Amyotrophic Lateral Sclerosis: A Focus on Disease Progression

Calvo, Ana C.; Manzano, Raquel; Mendonça, Deise M. F.; Muñoz, Marı́a Jesús; Zaragoza, Pilar; Osta, Rosario

doi:10.1155/2014/925101

Cited by 56 publications

(43 citation statements)

References 82 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Os sintomas iniciais geralmente aparecem entre 55 e 65 anos, com idade média de 64 anos. O início antes dos 30 anos, chamado de início juvenil esporádico, só é encontrado em 5% dos casos (CALVO et al, 2014;NUCCI, 2011).…”

Section: Introductionunclassified

Avaliação Da Sobrecarga Dos Cuidadores De Pessoas Com Esclerose Lateral Amiotrófica (Ela)

Almeida

Falcão

Carvalho

2017

Cad. Bras. Ter. Ocup.

View full text Add to dashboard Cite

Resumo: Introdução: Esclerose lateral amiotrófica (ELA) é uma desordem neurodegenerativa que resulta na morte seletiva de neurônios motores, causando fraqueza e atrofia muscular generalizada como principais sintomas. Ainda sem cura, o doente em tratamento requer assistência na mobilidade e atividades diárias. Cuidar de um paciente com ELA implica maior ou menor sobrecarga e tempo, demandando estratégias de redução do estresse e ampliação da qualidade de vida dos cuidadores. Nesse sentido, os grupos de apoio surgem como alternativas. Objetivo: O objetivo deste estudo é avaliar se há sobrecarga dos cuidadores de pacientes com ELA e os possíveis benefícios relacionados à participação no grupo de apoio específico a cuidadores. Método: Trata-se de um estudo descritivo e transversal, com aplicação da Escala de Sobrecarga do Cuidador -Zarit e entrevista sobre a participação no Grupo de Apoio Esperança para ELA, realizado em um hospital público do Recife. Foram avaliados sete cuidadores familiares e um profissional. Resultados: Após análise dos dados, verificou-se que a maioria dos cuidadores apresenta sobrecarga moderada e quase todos residem com o doente, o que pode contribuir para limitações e modificações no estilo de vida destes. A participação no grupo é reconhecida por todos como fonte de trocas e aprendizado sobre a doença, além de acolhedora de questões emocionais e dificuldades no cuidado. Conclusão: Conclui-se que esses cuidadores evidenciam sobrecarga moderada e se beneficiam do apoio recebido no Grupo Esperança para ELA. No entanto, outras estratégias podem ser necessárias para minimização dessa sobrecarga e segurança no cuidado ao doente. Palavras-chave: Esclerose Amiotrófica Lateral, Cuidadores, Efeitos Psicossociais da Doença, Determinação de Necessidades de Cuidados de Saúde. Evaluation of overloading on caregivers of people with Amyotrophic Lateral Sclerosis (ALS)Abstract: Introduction: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder that results in the selective death of motor neurons, with weakness and generalized muscle atrophy as primary symptoms. With cure yet to be found, the patients in treatment need assistance in mobility and daily activities. Taking care of a patient with ALS results in varying degrees of burden and time, demanding stress reduction strategies and an increase in the quality of life of caregivers. In this sense, support groups emerge as alternatives. Objective: The aim of this study was to assess whether caregivers of patients with ALS exhibit burden and the possible benefits from participating in a support group specifically designed for them. Method: This is a cross-sectional descriptive study that applied the Zarit Caregiver Burden Scale and Interview regarding participation in the "Hope for ALS" support group, at a public hospital in Recife, Brazil. Seven families' caregivers and one professional caregiver were assessed.Results: Data analysis showed that most caregivers exhibit moderate burden and nearly all live with the patient, which may contribute to...

show abstract

Section: Introductionunclassified

Avaliação Da Sobrecarga Dos Cuidadores De Pessoas Com Esclerose Lateral Amiotrófica (Ela)

Almeida

Falcão

Carvalho

2017

Cad. Bras. Ter. Ocup.

View full text Add to dashboard Cite

show abstract

“…This personalized medicine is the promise of biomarkers implementation into clinical trials. Various studies have evaluated potential biological, imaging, or clinical diagnostic markers to help in early diagnosis, but the literature on markers of clinical features or disease progression is modest [16,128,[207][208]. Numerous clinical measures have been linked with prognosis, but few have been used to predict prognosis and rare data are available regarding biological parameters to predict prognosis.…”

Section: Five-year Viewmentioning

confidence: 99%

Further development of biomarkers in amyotrophic lateral sclerosis

Blasco

Vourc’h

et al. 2016

Expert Review of Molecular Diagnostics

View full text Add to dashboard Cite

In this review, we specifically focus on biology and imaging markers. We detail the innovative field of 'omics' approach and imaging and explain their limits to be useful in routine practice. We describe the most relevant biomarkers and suggest some perspectives for biomarker research. Expert commentary: The successive failures of clinical trials in ALS underline the need for new strategy based on innovative tools to stratify patients and to evaluate their responses to treatment. Biomarker data may be useful to improve the designs of clinical trials. Biomarkers are also needed to better investigate disease pathophysiology, to identify new therapeutic targets, and to improve the performance of clinical assessments for diagnosis and prognosis in the clinical setting. A consensus on the best management of neuroimaging and 'omics' methods is necessary and a systematic independent validation of findings may add robustness to future studies.

show abstract

“…Numerous hypotheses about the etiopathology of ALS have been proposed (reviewed in [18–29]), including glutamate excitotoxicity, mitochondria dysfunction, oxidative stress, glial cell pathology, impaired axonal transport, protein aggregations, immune reactivity, neurotrophic factor deficits, and neuroinflammation.…”

Section: Introductionmentioning

confidence: 99%

Potential new complication in drug therapy development for amyotrophic lateral sclerosis

Garbuzova‐Davis

Thomson

Kurien

et al. 2016

Expert Review of Neurotherapeutics

View full text Add to dashboard Cite

Introduction Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by motor neuron degeneration in the brain and spinal cord. Treatment development for ALS is complicated by complex underlying disease factors. Areas covered Numerous tested drug compounds have shown no benefits in ALS patients, although effective in animal models. Discrepant results of pre-clinical animal studies and clinical trials for ALS have primarily been attributed to limitations of ALS animal models for drug-screening studies and methodological inconsistencies in human trials. Current status of pre-clinical and clinical trials in ALS is summarized. Specific blood-CNS barrier damage in ALS patients, as a novel potential reason for the clinical failures in drug therapies, is discussed. Expert opinion Pathological perivascular collagen IV accumulation, one unique characteristic of barrier damage in ALS patients, could be hindering transport of therapeutics to the CNS. Restoration of B-CNS-B integrity would foster delivery of therapeutics to the CNS.

show abstract

Amyotrophic Lateral Sclerosis: A Focus on Disease Progression

Cited by 56 publications

References 82 publications

Avaliação Da Sobrecarga Dos Cuidadores De Pessoas Com Esclerose Lateral Amiotrófica (Ela)

Avaliação Da Sobrecarga Dos Cuidadores De Pessoas Com Esclerose Lateral Amiotrófica (Ela)

Further development of biomarkers in amyotrophic lateral sclerosis

Potential new complication in drug therapy development for amyotrophic lateral sclerosis

Contact Info

Product

Resources

About